What Gynuity Health Projects does

Gynuity Health Projects is a New York-based non-profit research and technical assistance organization founded in 2003 that develops and disseminates scientific, clinical, and programmatic evidence in reproductive and maternal health for resource-poor environments worldwide. It operates seven core program areas: medication abortion, postpartum hemorrhage prevention and treatment, hypertensive disorders in pregnancy, contraception, period pills (menstrual regulation), pregnancy and birth care, and infectious disease. Its work spans more than 25 countries across North America, South America, Europe, Asia, Africa, and Central Asia, with research collaborators including WHO, FIGO, IPPF, Ipas, Stanford University, ANSIRH, Ibis Reproductive Health, Planned Parenthood affiliates, and government hospital systems.

The organization's principal 'products' are research outputs and clinical protocols rather than software. Notable technical and protocol assets include the TelAbortion direct-to-patient telemedicine abortion service model, a no-test medication abortion protocol that removes routine facility-based testing, multi-level pregnancy tests (MLPT) for at-home outcome assessment, computer-based and asynchronous screening tools for medication abortion eligibility, an updated systematic review of misoprostol-only regimens, and proof-of-concept research on ulipristal acetate paired with misoprostol as an alternative when mifepristone is unavailable. It also maintains the Map of Mifepristone Approvals, a public global regulatory tracking database. These assets are supported by an output of more than 300 peer-reviewed publications in journals including NEJM, Lancet, BMJ, and Contraception.

Gynuity generates no commercial revenue. Its operating model is grant- and donation-funded non-profit research and advocacy; all protocols, guidelines, and resources are made publicly available for free in multiple languages. The organization pursues a three-pillar approach of research, partnerships for policy and practice change, and strategic communications for impact, and is governed by a Board of Directors. It has published six consecutive annual reports (2020 through 2025) and corresponding IRS Form 990 filings, and in 2024 released a refreshed multi-year strategy, 'Maximizing Impact: Our Plan of Action for 2025 to 2030'. President Beverly Winikoff is a globally cited authority in mifepristone and misoprostol research and has received external recognition for contributions to safe abortion access.

Name

Gynuity Health Projects

Legal name

Gynuity Health Projects

Website

https://gynuity.org

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

11–50 employees

Short description

Gynuity Health Projects is a New York-based non-profit research organization that develops and disseminates clinical evidence and protocols in reproductive and maternal health, serving women, providers, and policymakers across more than 25 countries through grant-funded research and global partnerships.

Ownership category

akta.pro rank

Product category

Reproductive and Maternal Health Research

NAICS

Scientific Research and Development Services (5417), Family Planning Centers (62141), Family Planning Centers (621410)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Misc Health & Allied Services, Nec (8090)

akta.pro primary industry

Family Planning & Contraception (Including Abortion Care) (HLAKAJAG)

akta.pro secondary industries

Contraception & Family Planning Telehealth (birth control, counseling, follow-up) (HLALAHAB), Pregnancy & Prenatal Care Telehealth (OB tele-visits, prenatal monitoring) (HLALAHAC), Obstetrics & Gynecology (OB/GYN) Clinics (HLAFAJAA), Gynecology (General Non-Obstetric Care) (HLAKAJAL)

Keywords

• Reproductive health research
• Maternal health programs
• Medication abortion guidelines
• Postpartum hemorrhage interventions
• Clinical protocol development

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

1. Research Grants and Donations: Gynuity operates as a non-profit organization funded through research grants, charitable donations, and partnerships with donors. The organization develops and advocates for scientific evidence in reproductive and maternal health without a commercial revenue model.

Distribution channels1 record

Marketing channels6 records

Core offering

Gynuity Health Projects conducts clinical and programmatic research, and develops evidence-based protocols, guidelines, and educational resources for reproductive and maternal health. Its offerings include medication abortion research and training, the TelAbortion telemedicine service model, postpartum hemorrhage interventions including uterine balloon tamponade, hypertensive disorders in pregnancy programs, contraception research, "period pills" menstrual regulation work, Multi-Level Pregnancy Tests, and global mifepristone approvals tracking, all distributed as public goods to providers, policymakers, and institutions worldwide.

Product overview

Gynuity Health Projects is a reproductive and maternal health research organization that develops and advocates for evidence-based clinical protocols and guidelines rather than a traditional software product. The organization's core offerings center on research programs focused on medication abortion (mifepristone/misoprostol regimens), postpartum hemorrhage prevention/treatment, hypertensive disorders in pregnancy, contraception, and period pills. Key service offerings include TelAbortion (telemedicine for medication abortion), Multi-Level Pregnancy Tests for home-based follow-up, "No-Test" medication abortion protocols, and a global mifepristone approvals tracking map. These programs are supported by extensive clinical guidelines, training resources, research publications, and screening tools that the organization develops and distributes.

Differentiator

Problem solved

Functional benefit

Products and services

• Medication Abortion Research and Guidelines Comprehensive research and clinical guidelines on medication abortion using mifepristone and misoprostol, including protocols for various gestational ages and administration routes.
• TelAbortion Direct-to-patient telemedicine abortion service enabling remote consultation and mail delivery of abortion medications, evaluated extensively in the United States.
• Postpartum Hemorrhage Prevention and Treatment Research and implementation programs focused on misoprostol use, uterine balloon tamponade, and other interventions for preventing and treating postpartum hemorrhage.
• Period Pills Research and advocacy for menstrual regulation medications that treat delayed menses without requiring prior pregnancy confirmation.
• Hypertensive Disorders in Pregnancy Programs addressing preeclampsia and other hypertensive conditions through research on antihypertensive regimens and labor induction methods.
• Contraception Research programs examining contraceptive methods, including integration with medication abortion services and task-sharing strategies.
• Multi-Level Pregnancy Tests (MLPT) Semi-quantitative pregnancy tests developed for home-based follow-up after medication abortion, enabling remote outcome assessment.
• Medical Abortion Screening Tools Computer-based and asynchronous screening tools for evaluating medication abortion eligibility, including the MA ASAP demonstration study.
• "No-Test" Medication Abortion Protocol Sample protocol for providing medication abortion without routine facility-based tests before or after treatment, developed for pandemic response and expanded access.
• Mifepristone Global Approvals Map Interactive map and tracking system documenting mifepristone approval status across countries worldwide, maintained by Gynuity since 2017.

Quantifiable outcome

• TelAbortion service model enables direct-to-patient medication abortion via mail in the United States
• +3 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Ten partnerships are on record, tiered core and major.

• WHO (World Health Organization)coreStrategic or Co-development PartnerCollaborative relationship on postpartum hemorrhage research and guidelines. WHO co-authored publications with Gynuity staff including the prognostic accuracy meta-analysis on clinical markers for PPH and core outcome sets for PPH prevention and treatment.
• FIGO (International Federation of Gynecology and Obstetrics)coreStrategic or Co-development PartnerPartnership on misoprostol guidance and recommendations. FIGO updated its guidance on misoprostol-only regimens in collaboration with expert groups, with Gynuity involved in dissemination of the guidance covering medication abortion, miscarriage management, cervical preparation, fetal death, labor induction, and PPH management.
• International Planned Parenthood Federation (IPPF)coreStrategic or Co-development PartnerCollaborative partnership on minimum requirements for medical abortion package inserts. Joint publication of clinical guidelines and resources for improving abortion care access globally.
• IpascoreStrategic or Co-development PartnerPartnership on training guides for incomplete abortion management with misoprostol. Joint development of clinical training materials and resources.
• Stanford UniversitymajorStrategic or Co-development PartnerCollaborative research partner on medication abortion screening tools and studies including the MA ASAP pilot demonstration study. Multiple co-authored publications.
• Planned Parenthood (North Central States and Rocky Mountains)majorStrategic or Co-development PartnerClinical research partners on medication abortion studies including the MA ASAP demonstration project and TelAbortion service evaluation.
• Government Hospitals (Nepal, India, Pakistan, Mexico)majorImplementation/ SI/ Consulting PartnerImplementation partners in multiple countries for clinical research studies including outpatient medical induction studies in Nepal public hospitals and hypertensive disorders research in Indian hospitals.
• Mifepristone CoalitioncoreGTM or Marketing PartnerCoalition partner on countering abortion pill misinformation, specifically the 'abortion pill reversal' toolkit developed jointly to address misinformation.
• ANSIRH (Advancing New Standards in Reproductive Health)majorStrategic or Co-development PartnerResearch collaboration partner on U.S. self-managed abortion research roadmap and other studies.
• Ibis Reproductive HealthmajorStrategic or Co-development PartnerCollaborative partner on research roadmap for self-managed abortion in the United States.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Ibis Reproductive Health: Non-profit research organization focused on sexual and reproductive health evidence generation. Directly comparable as a similarly sized research-driven NGO collaborating with Gynuity on the self-managed abortion research roadmap.
• ANSIRH (Advancing New Standards in Reproductive Health): UCSF-based research program conducting rigorous, multidisciplinary research on reproductive health. Direct peer in reproductive health evidence generation and an active Gynuity research collaboration partner.
• Society of Family Planning: Membership society that funds and disseminates abortion and contraception research. Comparable as a research-grant and guideline-setting organization operating in the same evidence ecosystem as Gynuity.
• Ipas: Global non-profit working to advance reproductive justice through abortion care access, clinical training, and system strengthening. Directly comparable as a global reproductive health NGO and an active Gynuity implementation partner.
• Guttmacher Institute: Research and policy organization focused on sexual and reproductive health and rights. Directly comparable as a research-driven organization producing evidence that informs reproductive health policy and practice globally.

Broad incumbents

• Population Council: International non-profit conducting research and developing innovations in sexual and reproductive health, HIV, and gender equity. Comparable as a much larger, broader reproductive health research and product development organization.
• PATH: Global health non-profit driving innovation in reproductive health, maternal and newborn health, and other areas. Comparable as a large, multi-program global health organization with overlapping reproductive health mandates.
• FHI 360: Global development organization with a dedicated family planning and reproductive health portfolio spanning research, programs, and service delivery. Comparable as a large-scale, multi-country reproductive health implementer.
• EngenderHealth: Global non-profit working on gender equality, maternal health, and family planning programs across low-resource settings. Comparable as a reproductive and maternal health NGO with research and implementation components.

Emerging players

• Concept Foundation: Non-profit focused on increasing access to reproductive health medicines in low- and middle-income countries. Comparable as a smaller, niche reproductive health organization working on product access and evidence generation.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/gynuity

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gynuity Health Projects